Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CytomX Therapeutics (CTMX) Accumulated Expenses (2016 - 2025)

Historic Accumulated Expenses for CytomX Therapeutics (CTMX) over the last 12 years, with Q3 2025 value amounting to $12.4 million.

  • CytomX Therapeutics' Accumulated Expenses fell 2588.7% to $12.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $12.4 million, marking a year-over-year decrease of 2588.7%. This contributed to the annual value of $12.3 million for FY2024, which is 2989.37% down from last year.
  • Per CytomX Therapeutics' latest filing, its Accumulated Expenses stood at $12.4 million for Q3 2025, which was down 2588.7% from $11.5 million recorded in Q2 2025.
  • CytomX Therapeutics' Accumulated Expenses' 5-year high stood at $34.2 million during Q4 2021, with a 5-year trough of $11.4 million in Q1 2025.
  • In the last 5 years, CytomX Therapeutics' Accumulated Expenses had a median value of $19.3 million in 2021 and averaged $20.5 million.
  • Its Accumulated Expenses has fluctuated over the past 5 years, first surged by 6481.59% in 2022, then plummeted by 3675.78% in 2023.
  • Quarter analysis of 5 years shows CytomX Therapeutics' Accumulated Expenses stood at $34.2 million in 2021, then decreased by 28.58% to $24.4 million in 2022, then fell by 28.02% to $17.6 million in 2023, then decreased by 29.89% to $12.3 million in 2024, then increased by 0.57% to $12.4 million in 2025.
  • Its Accumulated Expenses stands at $12.4 million for Q3 2025, versus $11.5 million for Q2 2025 and $11.4 million for Q1 2025.